Patents by Inventor John C. Mathison

John C. Mathison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybrid cells producing monoclonal anti-CD14 antibodies
    Patent number: 7326569
    Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: February 5, 2008
    Assignee: The Scripps Research Institute
    Inventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
  • Worker specific health and safety training
    Publication number: 20040224293
    Abstract: A system, method, or apparatus for use in providing worker specific health and safety training (e.g., individualized training for each of a plurality of trainee individuals with respect to a particular configuration of respirator or other health and safety equipment and information).
    Type: Application
    Filed: May 8, 2003
    Publication date: November 11, 2004
    Applicant: 3M Innovative Properties Company
    Inventors: Paula J. Penning, John C. Mathison
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 6495332
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: December 17, 2002
    Assignees: The Sripps Research Institute, The Rockefeller University
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Methods and compositions for inhibiting CD14 mediated cell activation
    Patent number: 6444206
    Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.
    Type: Grant
    Filed: October 13, 1998
    Date of Patent: September 3, 2002
    Assignee: The Scripps Research Institute
    Inventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
  • Methods and compositions for ameliorating the symptoms of sepsis
    Publication number: 20020034509
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Application
    Filed: October 2, 2001
    Publication date: March 21, 2002
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 6297049
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: October 2, 2001
    Assignee: The Scripps Research Institute
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 6045795
    Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CDl4 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: April 4, 2000
    Assignee: The Scripps Research Institute
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
  • Methods and compositions for inhibiting CD14 mediated cell activation
    Patent number: 5820858
    Abstract: This invention provides monoclonal antibodies that bind to the cell surface CD14 receptor and soluble CD14 receptor. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent LPS-associated disorders, such as sepsis.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: October 13, 1998
    Assignee: The Scripps Research Institute
    Inventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
  • Methods and compositions for ameliorating the symptoms of sepsis
    Patent number: 5730980
    Abstract: The present invention concerns a method of treating CD14-mediated host inflammatory response to LPS often associated with sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.
    Type: Grant
    Filed: October 25, 1994
    Date of Patent: March 24, 1998
    Assignee: The Scripps Research Institute
    Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison